Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| APLS | Apellis Pharmaceuticals | $40.31 | $23.22 | 135.84% | 47M | $2.2B | $16.10$40.45 |
| MASK | 3 E Network Technology Group | $2.51 | $1.27 | 102.02% | 76.8M | $28M | $1.19$100.00 |
| KIDZ | Classover | $3.30 | $1.25 | 60.98% | 74.1M | $2.5M | $2.01$532.50 |
| CNTA | Centessa Pharmaceuticals Plc | $39.93 | $12.35 | 44.76% | 23.2M | $3.7B | $9.60$40.26 |
| PASG | Passage Bio | $7.70 | $1.52 | 24.59% | 27.1K | $20M | $5.12$20.00 |
| AGIO | Agios Pharmaceuticals | $36.25 | $6.64 | 22.43% | 78.1K | $1.7B | $22.24$46.00 |
| CRMU | Themes ETF Trust - Leverage Shares 2x Long Crml Daily ETF | $4.84 | $0.85 | 21.17% | 28.2K | - | $3.99$15.25 |
| UGRO | Urban-gro | $24.82 | $4.20 | 20.38% | 2.6M | $15M | $2.02$37.00 |
| MODD | Modular Medical | $5.44 | $0.89 | 19.61% | 199.7K | $636M | $3.55$34.50 |
| BAER | Bridger Aerospace Group | $2.04 | $0.32 | 18.61% | 413.5K | $96M | $1.02$3.44 |
| ALKS | Alkermes Plc | $35.63 | $5.48 | 18.18% | 237.2K | $5.0B | $25.17$36.32 |
| NPT | Texxon | $5.60 | $0.83 | 17.40% | 4.4M | $106M | $3.14$22.38 |
| AURE | Aurelion | $2.10 | $0.31 | 17.32% | 7.1K | $62M | $1.50$14.60 |
| VOR | Vor Biopharma | $17.18 | $2.48 | 16.87% | 997.5K | $610M | $2.62$65.80 |
| RMCO | Royalty Management | $2.83 | $0.40 | 16.58% | 33.1K | $37M | $0.91$5.00 |
| DWSN | Dawson Geophysical | $3.07 | $0.43 | 16.29% | 320.7K | $82M | $1.08$5.54 |
| TBN | Tamboran Resources | $51.62 | $7.18 | 16.16% | 93.2K | $1.0B | $17.29$51.79 |
| UUUG | Themes ETF Trust - Leverage Shares 2x Long Uuuu Daily ETF | $9.70 | $1.33 | 15.89% | 153.5K | - | $8.18$30.00 |
| BAIG | Themes ETF Trust - Leverage Shares 2x Long Bbai Daily ETF | $2.57 | $0.35 | 15.75% | 185.1K | - | $2.16$36.03 |
| NCEL | NewcelX | $2.15 | $0.27 | 14.36% | 1.8K | $8.6M | $1.83$30.80 |
| TRUG | TruGolf | $5.19 | $0.65 | 14.21% | 117.9K | $2.2M | $3.50$210.00 |
| KSCP | Knightscope | $3.87 | $0.48 | 13.99% | 498.4K | $45M | $2.45$10.14 |
| CVKD | Cadrenal Therapeutics | $4.80 | $0.55 | 12.94% | 38.2K | $9.9M | $4.21$19.03 |
| JFU | 9f | $3.39 | $0.21 | 6.60% | 4.3K | $28M | $1.01$9.48 |
Related Articles
Featured Article
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst
Cory Renauer|Oct 29, 2024
It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead.
2 Best Growth Stocks to Buy in April
George Budwell, PhD|Apr 3, 2023
Takeover interest is spurring these two biotech stocks higher.
Wall Street Upgraded This Stock's Price Target After a New Approval: Is It a Buy?
James Halley|Feb 27, 2023
The company's lead therapy was just approved for another indication.
Want to Make Money in Biotech? Do This First
Brian Orelli, PhD and Keith Speights|May 7, 2021
Keeping track of upcoming events is important.
Why Alkermes' Q4 Results Were Better Than They Might Seem
Keith Speights|Feb 11, 2021
The biotech posted a big year-over-year sales decline. But there was a good reason for it.
4 Reasons Agios' Oncology Deal Should Please Investors
Cory Renauer|Dec 22, 2020
Agios' newly revamped business strategy is an extreme departure from the company's original mission, but it's a great deal for shareholders.
2 Mid-Cap Healthcare Stocks to Buy Now
Cory Renauer|Sep 5, 2020
These drugmakers are in the sweet spot to provide market-beating returns.
The Coronavirus Pandemic Will Delay 2020 IPOs
Joe Tenebruso|Mar 15, 2020
COVID-19 and initial public offerings don’t go well together.
Gene Therapy Biotech Passage Bio IPOs
Brian Orelli, PhD|Feb 28, 2020
The clinical-stage biotech raised $216 million.
Is Apellis Pharmaceuticals a Buy?
Maxx Chatsko|Feb 3, 2020
The pre-commercial company is looking to take on a $23 billion industry leader. Promising late-stage clinical results suggest it may have a shot.
